Chemed (NYSE:CHE – Get Free Report) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 23.300-23.700 for the period, compared to the consensus estimate of 23.520. The company issued revenue guidance of -. Chemed also updated its FY24 guidance to $23.30-23.70 EPS.
Analyst Upgrades and Downgrades
Several equities analysts recently weighed in on the company. Oppenheimer lifted their price target on Chemed from $625.00 to $650.00 and gave the company an outperform rating in a research note on Thursday, February 29th. Royal Bank of Canada lifted their price target on Chemed from $604.00 to $712.00 and gave the company an outperform rating in a research note on Monday, March 4th.
Get Our Latest Analysis on Chemed
Chemed Price Performance
Chemed (NYSE:CHE – Get Free Report) last released its quarterly earnings data on Tuesday, February 27th. The company reported $6.60 EPS for the quarter, beating analysts’ consensus estimates of $6.25 by $0.35. Chemed had a return on equity of 32.29% and a net margin of 12.03%. The firm had revenue of $585.90 million for the quarter, compared to analysts’ expectations of $586.64 million. During the same period in the prior year, the firm posted $5.39 earnings per share. The firm’s quarterly revenue was up 7.2% on a year-over-year basis. Analysts expect that Chemed will post 21.99 EPS for the current year.
Chemed Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Friday, March 15th. Stockholders of record on Monday, February 26th were paid a $0.40 dividend. This represents a $1.60 annualized dividend and a dividend yield of 0.26%. The ex-dividend date of this dividend was Friday, February 23rd. Chemed’s payout ratio is currently 8.93%.
Insider Activity
In other Chemed news, EVP Spencer S. Lee sold 2,000 shares of the firm’s stock in a transaction on Thursday, March 28th. The stock was sold at an average price of $641.65, for a total value of $1,283,300.00. Following the sale, the executive vice president now directly owns 20,760 shares in the company, valued at $13,320,654. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, VP Brian C. Judkins sold 11,158 shares of the business’s stock in a transaction that occurred on Wednesday, March 20th. The stock was sold at an average price of $645.00, for a total transaction of $7,196,910.00. Following the sale, the vice president now owns 1,422 shares of the company’s stock, valued at approximately $917,190. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Spencer S. Lee sold 2,000 shares of Chemed stock in a transaction that occurred on Thursday, March 28th. The stock was sold at an average price of $641.65, for a total value of $1,283,300.00. Following the transaction, the executive vice president now owns 20,760 shares of the company’s stock, valued at $13,320,654. The disclosure for this sale can be found here. Over the last three months, insiders have sold 15,808 shares of company stock worth $10,184,531. Corporate insiders own 3.32% of the company’s stock.
About Chemed
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.
Further Reading
- Five stocks we like better than Chemed
- How to Calculate Return on Investment (ROI)
- High-Yield Texas Instruments Could Hit New Highs Soon
- What are earnings reports?
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- What is MarketRank™? How to Use it
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.